An open, observational study was conducted in five European countries to obtain information concerning the profile of patients responding to sulpiride. A total of 1356 patients were evaluable for analysis. The majority of patients (81.1%) had at least three principal somatic complaints; asthenia being the most common, followed by dizziness and headache. Most patients (76.0%) were rated as moderately to extremely ill according to the Clinical Global Impression (CGI) severity score. All patients received oral sulpiride for 3 -6 weeks (mean dose, 175 mg/day). Sulpiride demonstrated good efficacy as shown by a reduction in the incidence and severity of somatic complaints, and an improvement in CGI severity score and the Hopkins Symptom Checklist -58 items. Based on a CGI rating of very much or much improved, 58.2% of patients were rated as responders. Sulpiride was well tolerated. There were no serious adverse events and only 16 patients (1.2%) were withdrawn prematurely from the study due to adverse events. There were no differences between the countries regarding the patients' profile or their response to sulpiride. Thus, the prescription profile of sulpiride appears not to be culturally dependent.
Introduction
Sulpiride is a substituted benzamide that specifically blocks limbic dopamine D 2 and D 3 receptors and is devoid of affinity for other receptors. 1 The fact that it has only a very weak effect on striatal dopamine receptors may account for its low incidence of extrapyramidal effects. At low doses, sulpiride preferentially blocks pre-synaptic receptors, thus inducing an increase in dopaminergic transmission. This may be responsible for the activating properties of sulpiride 2 and its efficacy in a broad range of conditions. The principal indications for sulpiride include neurotic states with inhibition, and psychosomatic components of organic diseases. Numerous clinical studies have confirmed that F Rouillon, G Rahola, M Van Moffaert et al.
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sulpiride is effective and compares well with a number of other psychotropic agents including diazepam, trazodone, tianeptine and amitriptyline. 3 -18 The use of sulpiride is characterized by diverse indications that vary widely between countries. It is sometimes used to treat symptoms of functional pathology and, in other cases, to treat psychiatric disorders. Unfortunately, data concerning the patient profile that has emerged from previous clinical trials is unclear, a fact that is compounded by the varying classifications of somatic symptoms that are currently available. The aim of this multinational observational study was therefore to gain a better insight into the social, demographic and clinical profile of patients who respond to sulpiride based on information from international classifications and evaluation tools applied to current prescribers.
Patients and methods PATIENTS
This open, observational cohort study was conducted by 1467 investigators, who were either general practitioners or specialists, in five European countries (Germany, Spain, France, Belgium and Portugal). Patients who were considered likely to benefit from sulpiride treatment were eligible for inclusion in the study. Exclusion criteria included a current or previous diagnosis of psychotic disorder and/or treatment with sulpiride within the last month.
All patients received oral sulpiride for between 3 and 6 weeks; the daily dosage of sulpiride was selected by each investigator based on their clinical experience.
EFFICACY ASSESSMENTS
The patients were assessed at baseline and at the end of sulpiride treatment. A somaticcomplaints checklist, covering 24 somatic complaints, was completed by the investigator at both visits. The Clinical Global Impression (CGI) 19 scale was also used by the investigator to assess the severity of illness at both visits and the level of improvement or worsening at the final visit.
The patients were required to record their symptoms at both visits using the Hopkins Symptom Checklist -58 items (HSCL-58). 20 -24 This is a self-administered questionnaire involving somatic and psychological symptoms and covering five conditions: depression, obsessive-compulsiveness; anxiety; somatization; and hostility. 25 Each item is scored on a scale of 0 (extremely) to 3 (not at all). The global score is then calculated as the sum of the scores for each item. Seven subscores are also calculated as follows: interpersonal sensitivity (10 items); pain somatization (seven items); inhibition and retardation (seven items); digestive (three items); neurovegetative (eight items); obsessional and sleeping disorders (four items); and depressed mood (six items).
SAFETY ASSESSMENT
Safety was assessed by spontaneous reporting of adverse events. A serious adverse event was defined as one that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, or results in significant disability or incapacity.
DATA ANALYSES
As this was an open study, the analyses were mainly descriptive. The main objective of the analyses was to determine the most relevant characteristics of patients who respond to sulpiride treatment. Patients were considered to be responders if they had an investigator's CGI rating of 'very much' or 'much improved' at the final visit.
The HSCL-58 score at baseline and the change at the final visit were evaluated using factor-analysis in which the demographic, 306 symptomatic and social profiles of the responders and non-responders were entered as illustrative variables. A logistic regression analysis was performed separately for responders and non-responders using a stepwise procedure and the HSCL items as dependent variables. A multivariate analysis was also performed to evaluate any potential relationships between the HSCL-58 subscores and the investigator's speciality with responder status. Table 1 . More than two-thirds were female and almost half (43%) were in the 40 -60 year age group. The majority of patients were either employed or retired, and more than two-thirds were either married or living with a partner. Approximately two-thirds of patients had a concomitant illness (psychiatric or physical) and were taking concomitant medication. 
Results

PATIENTS
EFFICACY ASSESSMENTS Somatic complaints
At baseline, most patients complained of asthenia (83.6%) and approximately threequarters reported dizziness (76.6%) and headache (76.3%) ( Table 2 ). Thirteen somatic complaints were observed in more than half the patients. The majority of patients (81.1%) had at least three principal somatic complaints. With the exception of dizziness, which was reported as severe in 22% of cases, all somatic complaints were rated as mild or moderate in more than 80% of cases.
As shown in Table 2 , the percentage of patients reporting each symptom was considerably reduced at the final visit. The most common symptom remained asthenia, which was seen in 61.4% of patients. In marked contrast to baseline, no other symptom was observed in more than 50% of the patients. The percentage of patients whose symptoms had disappeared at 
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the final visit ranged from 26.6% for asthenia to 68.3% for vomiting. There was also a reduction in the severity of complaints; with the exception of sexual disorders, which were reported as severe in 14.4% of cases, more than 90% of complaints were rated as mild or moderate. Similarly, the percentage of patients whose symptoms were moderate or severe was reduced for all symptoms at the final visit.
Clinical global impression severity score
The CGI severity of illness score at baseline and at the final visit is shown in Fig. 1 . In agreement with the improvement in somatic complaints, there was a clear reduction in the CGI severity of illness after treatment.
The percentage of patients who were rated as moderately, markedly, severely or extremely ill was reduced from 76.0% at baseline to 48.3% at the final visit.
Almost 90% of patients (89.8%) were considered to have improved at the final visit, with 45.1% being much improved and 13.1% very much improved; only 0.9% of patients were considered to have worsened. Based on the definition of a CGI rating of very much or much improved at the final visit, 58.2% of patients (n = 788) were rated as responders. The improvement seen at the final visit was not dependent upon the severity of the illness or the number of somatic complaints at baseline.
Hopkins Symptom Checklist -58 items score
The mean HSCL-58 global and subscores at baseline and at the final visit are shown in Table 3 . Both the mean global score and all the subscores were increased at the final visit. Thus, the patients' self-assessment of 
RESPONDER PROFILE
The sex distribution was similar for responders and non-responders. The mean age of responders was slightly less than that of non-responders (50.4 years versus 52.9 years) and the percentage of patients who were employed was somewhat higher among the responders than the nonresponders (49.2% versus 40.3%). There was a corresponding difference between the percentage of patients who were retired in the responder and non-responder groups (29.1% versus 38.9%). Patients who responded were less likely to have a personal history of psychiatric disease than nonresponders (25.5% versus 34.3%), although no differences were apparent in family history of psychiatric disease. In addition, responders had less concomitant psychiatric illness (18.7% versus 28.7%), less concomitant physical illness (48.7% versus 60.3%) and were less likely to be taking concomitant medication (62.8% versus 75.2%) than non-responders.
The mean dose of sulpiride was similar in responders and non-responders (176 mg/day versus 174 mg/day); the mean duration of treatment was 5 weeks in both groups. The percentage of responders was higher than that of non-responders for all types of investigators with the exception of neurologists (43% response rate) and neuropsychiatrists (40% response rate).
Multivariate analyses revealed no relationship between responder status and the investigator's speciality or the HSCL-58 global score or subscores. According to the stepwise procedure, however, the likelihood of being a responder increased significantly with improvement in the HSCL-58 inhibition and retardation subscore (odds ratio, 1.04; P = 0.0016). Similarly, patients treated by a neuropsychiatrist were significantly less likely to be a responder than those treated by a general practitioner (odds ratio, 0.40; P = 0.0001). Factor analysis revealed no correlation between responder status and demographic characteristics.
The rate of response was similar in all five countries involved in the study, ranging from 54.4% in Germany to 64.8% in Spain.
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SAFETY ASSESSMENT
There were no deaths or other serious adverse events. Sulpiride was well tolerated, with adverse events being reported by only 61 patients (4.5%). The most common events included galactorrhoea (n = 12), breast pain (n = 3) and hyperprolactinaemia (n = 3). Among the three patients with hyperprolactinaemia, one was without clinical signs and two were associated with galactorrhoea. Sixteen patients (1.2%) withdrew from the study prematurely due to adverse events; among these, galactorrhoea was reported in three patients and various other events were reported once.
Discussion
The somatoform disorders are a group of conditions that comprise physical symptoms for which no adequate medical explanation can be found. These somatic complaints are serious enough to cause persistent distress for the patient and to impair their ability to function in everyday life. 26 They are also likely to be associated with the development of other mental disorders. The diagnostic class of somatoform disorders is relatively new, being first introduced into the Diagnostic and Statistical Manual of Mental Disorders (DSM) classification in 1980. DSM-IV 27 recognizes five specific conditions (somatization disorder, conversion disorder, hypochondriasis, body dysmorphic disorder and pain disorder) as well as two residual categories. This classification has also been adopted in the Tenth Revision of the International Classification of Diseases (ICD-10), 28 with the addition of a supplementary category, somatoform autonomic dysfunction. These diagnostic criteria have been frequently criticized, however, and work is still ongoing to improve their diagnostic and prognostic value. 29 -31 Somatoform disorders are commonly encountered in general practice, with estimates suggesting that somatization may account for as many as 40% of patients seeking medical treatment for their complaint. 32 Despite this, the recognition, diagnosis and treatment of somatoform disorders can be problematic. Somatoform disorders represent a considerable health concern as physicians may invest considerable time and resources in the investigation and medical treatment of patients with these conditions. 33 Moreover, a diagnosis of a somatoform disorder is frequently totally unacceptable to the patient who may be convinced that his or her condition has a physical origin.
The patients treated with sulpiride in the current study presented with both somatic and psychiatric symptoms consistent with a diagnosis of a somatoform disorder. More than three-quarters of these patients had at least three somatic symptoms. This is in agreement with the mean number of somatic symptoms reported in a large-scale (n = 5604) collaborative study of psychological problems in general healthcare. 34 More than three-quarters of the patients were rated as at least moderately ill by the investigator. It is interesting to note, however, that severity of illness was not always correlated to the intensity of somatic complaints. Patients rated as having a severe disease did not necessarily have severe symptoms, but instead may have had a cluster of symptoms that they considered mild or moderate.
A rising awareness of the prevalence and costs of somatoform disorders has resulted in increased efforts to find suitable treatment options. 35 As most patients are seen in primary-care settings, it is important that treatments are cost-effective, easily and readily available and do not require special F Rouillon, G Rahola, M Van Moffaert et al.
Sulpiride in somatoform disorders psychiatric skills. Pharmacotherapy meets these criteria and is also generally better accepted by the patients who, as previously discussed, may be convinced of the physical nature of their condition and unwilling to accept psychological treatment. Anxiolytics have been widely used in the past, although there are concerns about dependence, especially as many patients with somatoform disorders require long-term treatment. Antidepressants, particularly those with sedative effects, may also be beneficial, although opinions differ as to their effectiveness.
Recently, attention has focused on the use of low-dose neuroleptics, especially the substituted benzamides such as sulpiride. Their efficacy in both somatoform and functional disorders is thought to be based on their ability to selectively cause dopamine blockade in the area postrema, the hypothalamo-hypophysial system and the mesolimbic pathways. Sulpiride has proved more effective than diazepam for depression symptoms and somatization in patients suffering from ambulatory neuroses 3 and more effective than tianeptine for somatic complaints in patients with depression. 14 In a double-blind study of elderly patients with psychosomatic disorders, sulpiride was at least as effective as trazodone and had particularly marked effects on headaches, palpitations and obsessional phobia. 12 Another double-blind study involving 74 patients with somatoform disorders showed that sulpiride was significantly more effective than placebo in reducing the number of somatic symptoms. Other studies have shown that sulpiride can be used to treat functional and psychosomatic disorders of the digestive tract, such as diarrhoea, constipation and abdominal pain, 10 and has significant benefits after 1 week in patients with spasmodic colitis or dyspepsia. 11 A recent, large-scale study conducted in 669 patients with pain disorder of gastrointestinal origin confirmed that sulpiride reduces gastrointestinal pain and other gastroenterological symptoms, such as disturbances of bowel movements and nausea/vomiting, and that these effects are associated with significant improvements in quality of sleep, appetite and everyday activities. 7 Similarly, sulpiride was reported to be very effective in patients with angina pectoris associated with symptoms of anxiety (when given with drugs to treat coronary insufficiency) 4 and in patients with psychogenic pain and rheumatological disease. 6 The efficacy and safety of sulpiride in patients with somatoform disorders was confirmed in the current large-scale study. Sulpiride treatment was associated with a marked reduction in the incidence and severity of somatic complaints, as well as improvement in CGI severity score and the patient-rated HSCL-58. The mean dose of 175 mg/day was in agreement with the dose of sulpiride usually found to be effective in somatoform disorders (150 -300 mg/day). 36 Based on a CGI rating of very much or much improved, 58.2% of patients were responders. The profile of the typical responder was a patient aged 50 years or less, employed, with little history of psychiatric disorders and few concomitant diseases or treatments. Patients were also more likely to be responders if they were treated by a general practitioner than by specialist neurologists or neuropsychiatrists; this is probably related to the fact that patients consulting a specialist are likely to have a more complex or serious condition. The chance of being a responder also increased significantly with improvement in the HSCL-58 inhibition and retardation subscore. This is in agreement with a previous study conducted in 50 depressed patients in which sulpiride was significantly more effective than amitriptyline in improving certain F Rouillon, G Rahola, M Van Moffaert et al.
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depressive symptoms, most notably the psychomotor retardation factor of the Hamilton Depression Rating Scale. 17 There were no differences between the countries regarding the patients' profile or their response to sulpiride. Similar results were found in a previous general healthcare study, conducted at 15 sites in Europe, Asia and South America, in which psychological distress and somatic complaints were found not to be influenced by culture. 34 This indicates that the prescription of sulpiride should not be limited to specific indications in specific countries and that it can be specifically recommended for patients with somatoform disorders.
